arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Accustem Sciences Inc.

ACUT
— Price unavailable
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
23 Visible periods
23 Metrics
Peer-ranked Benchmarks
Price Chart
53
Health
Fair
Bullish
auto_awesome

Analytical Summary

Accustem Sciences Inc. shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap —
Dividend Yield —
Revenue Growth —
Op. Margin -256.7%
ROIC 4.8% ↘
FCF / Share $-0.02 ↗
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity —
info Valuation on last close.

23-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-252.57K
↑ +37.1% —
FCF / Share Free cash flow per share
$-0.02
↑ +33.5% —
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Returns
97
Financial Health ↓
5
Cash Quality →
39

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 6 years · 23 quarters